Premium
[P1–142]: DNA METHYLATION DYNAMICS IN ALZHEIMER's DISEASE DIAGNOSIS AND PROGRESSION
Author(s) -
Vasanthakumar Aparna,
Davis Justin W.,
Idler Kenneth,
Kim Sungeun,
Nho Kwangsik,
Nudelman Kelly N.H.,
Faber Kelley,
Bai Yuchen,
Foroud Tatiana M.,
Estrada Karol,
Li Qingqin,
Saykin Andrew J.,
Waring Jeffrey
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.209
Subject(s) - dnam , dna methylation , confidence interval , cpg site , oncology , medicine , disease , cohort , methylation , alzheimer's disease , alzheimer's disease neuroimaging initiative , biology , gene , genetics , gene expression
explore differential cerebral amyloid burden between carriers and non-carriers of APOE-Ɛ4 and Ɛ2. Linear regression model was applied to investigate the correlation between APOE allele dosage and FBB-PET. Statistical analyses and Meta-analysis were performed using SPSS and OpenMeta, respectively. In case of heterogeneity between studies, DerSimonian and Liard method was used. Results:We found a significant association between APOE Ɛ4 and SCD diagnosis [OR1⁄41.61(1.21 – 2.16); p1⁄40.001]. Meta-analysis of the present results with prior studies (n1⁄49,567), identified heterogeneity in the APOE Ɛ4 effect among series (I21⁄453%, p1⁄40.03), reaching nominal statistical significance [OR1⁄41.23 (1.01 – 1.51]; p1⁄40.05]. In addition, SCD individuals carriers of APOE-Ɛ4 presented higher risk to suffer AD than non-carriers [OR1⁄41.95(1.47 – 2.60); p1⁄42.69e-06]. Furthermore, significant differences were found in cerebral amyloid burden between carriers and non-carriers of APOE-Ɛ4 (p1⁄41.62e-05). However, APOE allele dosage only explained 9% of FBB-PET levels variation. Conclusions: Our study points out to the existence of a preclinical AD subgroup within the SCD population. We proposed that the variation in cerebral amyloid levels is partially explained by the APOE allele dosage, suggesting that other genetic or epigenetic factors are involved in this trait. Poster Presentation